Background/Objectives: Clinical trials of dupilumab have shown efficacy in treating
| INTRODUCTION
Dupilumab is a human monoclonal antibody that binds to the interleukin (IL)-4 receptor subunit alpha shared by both IL-4 and IL-13 receptors and inhibits signaling of IL-4 and IL-13. 1 These cytokines are released in type 2 helper T (Th2) cell inflammatory pathways, which are known to be dysregulated in several atopic conditions including atopic dermatitis (AD). 2 Clinical trials of dupilumab have shown efficacy in adult patients with moderate-to-severe AD with a significantly greater percent of treated patients achieving clear or almost clear skin as compared to placebo. 3, 4 This medication has generally been well tolerated with less concern for toxicity as compared to other systemic medications used for AD.
Currently, the prevalence of AD is on the rise with over 20% of children affected, 5 33% having moderate-to-severe disease. 6 There is an increasing need for more effective treatments in the pediatric population, especially for patients with severe disease in which treatment is limited to systemic therapies carrying the risk of immunosuppression as well as other medication-specific side effects. 7 Additionally, there are sparse data to guide the use of these systemic We present this case series to describe the efficacy and safety profile of long-term, off-label dupilumab treatment in six pediatric patients in our clinical cohort.
| ME TH ODS
Patients less than 18 years of age were identified from a cohort of patients treated with dupilumab for moderate-to-severe AD between
March 2017 and May 2018. Because this was a case series and patients were deidentified, we did not consult the institutional review board for approval. All patients had a general consent signed by a parent stating that their information in the medical record may be used for research. This study followed the tenets of the Declaration of Helsinki.
All identified patients had received a loading dose with subsequent biweekly injection. Patients weighing less than 40 kg received half of the medication in each commercially available 2-mL syringe.
Because the syringes were unmarked, these patients returned to clinic where 1 mL of the medication was wasted into a graduated cylinder prior to injection. All patients were encouraged to continue Given the increased incidence of conjunctivitis reported in clinical trials of adult patients with AD, 9 all patients were warned of the potential for this side effect and instructed to contact the clinic if symptoms of eye irritation developed. Patients were further warned of an increased risk of infection, potential for injection site reaction, and that dupilumab had not been approved for children by the FDA.
| RESULTS
A total of six pediatric patients (four female) were identified with an average age of 10.8 years (range: 7-15). All patients had an IGA of 4 (severe) and an average BSA of 55% (range: 35%-70%) at the time of dupilumab initiation (Table 1) All six patients had an average IGA and BSA of 1.5 (range 1-2) and 25% (range: 10%-50%), respectively after mean treatment duration of 8.5 months (range: 6-11 months). Three patients (50%) achieved almost clear skin (IGA = 1) ( Table 1) The open-label phase 2 trial of dupilumab in children and adolescents stratified patients into four groups based on age (6-11 and 12-17 years) and weekly dosage (2 or 4 mg/kg). While both dose regimens had similar efficacy, as determined by improvement in EASI scores, the 4-mg/kg dose was associated with more adverse events including conjunctivitis, infections, and injection site reactions; however, these events did not lead to the discontinuation of therapy.
Currently, commercially available dupilumab is supplied in unmarked, prefilled syringes containing 2 mL (300 mg) of medication, the biweekly dose FDA approved for adults. We chose to treat our patients with either the full or measured half doses. Using this strategy, the calculated weight-based dosing was, in some cases, signifi- 
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